These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 37211044)
1. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. Oliveira M; Falato C; Cejalvo JM; Vila MM; Tolosa P; Salvador-Bofill FJ; Cruz J; Arumi M; Luna AM; Guerra JA; Vidal M; Martínez-Sáez O; Paré L; González-Farré B; Sanfeliu E; Ciruelos E; Espinosa-Bravo M; Pernas S; Izarzugaza Y; Esker S; Fan PD; Parul P; Santhanagopal A; Sellami D; Villacampa G; Ferrero-Cafiero JM; Pascual T; Prat A Ann Oncol; 2023 Aug; 34(8):670-680. PubMed ID: 37211044 [TBL] [Abstract][Full Text] [Related]
2. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Brasó-Maristany F; Ferrero-Cafiero JM; Falato C; Martínez-Sáez O; Cejalvo JM; Margelí M; Tolosa P; Salvador-Bofill FJ; Cruz J; González-Farré B; Sanfeliu E; Òdena A; Serra V; Pardo F; Luna Barrera AM; Arumi M; Guerra JA; Villacampa G; Sánchez-Bayona R; Ciruelos E; Espinosa-Bravo M; Izarzugaza Y; Galván P; Matito J; Pernas S; Vidal M; Santhanagopal A; Sellami D; Esker S; Fan PD; Suto F; Vivancos A; Pascual T; Prat A; Oliveira M Nat Commun; 2024 Jul; 15(1):5826. PubMed ID: 38992028 [TBL] [Abstract][Full Text] [Related]
3. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Pascual T; Oliveira M; Ciruelos E; Bellet Ezquerra M; Saura C; Gavilá J; Pernas S; Muñoz M; Vidal MJ; Margelí Vila M; Cejalvo JM; González-Farré B; Espinosa-Bravo M; Cruz J; Salvador-Bofill FJ; Guerra JA; Luna Barrera AM; Arumi de Dios M; Esker S; Fan PD; Martínez-Sáez O; Villacampa G; Paré L; Ferrero-Cafiero JM; Villagrasa P; Prat A Front Oncol; 2021; 11():638482. PubMed ID: 33968735 [No Abstract] [Full Text] [Related]
4. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial. Krop IE; Masuda N; Mukohara T; Takahashi S; Nakayama T; Inoue K; Iwata H; Yamamoto Y; Alvarez RH; Toyama T; Takahashi M; Osaki A; Saji S; Sagara Y; O'Shaughnessy J; Ohwada S; Koyama K; Inoue T; Li L; Patel P; Mostillo J; Tanaka Y; Sternberg DW; Sellami D; Yonemori K J Clin Oncol; 2023 Dec; 41(36):5550-5560. PubMed ID: 37801674 [TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors. Lu Y; Shimizu S; Sawamura R; Tajima N; He L; Lee M; Abutarif M; Shi R J Clin Pharmacol; 2023 Jan; 63(1):77-90. PubMed ID: 36053771 [TBL] [Abstract][Full Text] [Related]
6. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. Yu HA; Baik C; Kim DW; Johnson ML; Hayashi H; Nishio M; Yang JC; Su WC; Gold KA; Koczywas M; Smit EF; Steuer CE; Felip E; Murakami H; Kim SW; Su X; Sato S; Fan PD; Fujimura M; Tanaka Y; Patel P; Sternberg DW; Sellami D; Jänne PA Ann Oncol; 2024 May; 35(5):437-447. PubMed ID: 38369013 [TBL] [Abstract][Full Text] [Related]
7. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. Koyama K; Ishikawa H; Abe M; Shiose Y; Ueno S; Qiu Y; Nakamaru K; Murakami M PLoS One; 2022; 17(5):e0267027. PubMed ID: 35503762 [TBL] [Abstract][Full Text] [Related]
8. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Yu HA; Goto Y; Hayashi H; Felip E; Chih-Hsin Yang J; Reck M; Yoh K; Lee SH; Paz-Ares L; Besse B; Bironzo P; Kim DW; Johnson ML; Wu YL; John T; Kao S; Kozuki T; Massarelli E; Patel J; Smit E; Reckamp KL; Dong Q; Shrestha P; Fan PD; Patel P; Sporchia A; Sternberg DW; Sellami D; Jänne PA J Clin Oncol; 2023 Dec; 41(35):5363-5375. PubMed ID: 37689979 [TBL] [Abstract][Full Text] [Related]
9. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, Jänne PA; Baik C; Su WC; Johnson ML; Hayashi H; Nishio M; Kim DW; Koczywas M; Gold KA; Steuer CE; Murakami H; Yang JC; Kim SW; Vigliotti M; Shi R; Qi Z; Qiu Y; Zhao L; Sternberg D; Yu C; Yu HA Cancer Discov; 2022 Jan; 12(1):74-89. PubMed ID: 34548309 [TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan. Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422 [TBL] [Abstract][Full Text] [Related]
12. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Nuciforo P; Pascual T; Cortés J; Llombart-Cussac A; Fasani R; Paré L; Oliveira M; Galvan P; Martínez N; Bermejo B; Vidal M; Pernas S; López R; Muñoz M; Garau I; Manso L; Alarcón J; Martínez E; Rodrik-Outmezguine V; Brase JC; Villagrasa P; Prat A; Holgado E Ann Oncol; 2018 Jan; 29(1):170-177. PubMed ID: 29045543 [TBL] [Abstract][Full Text] [Related]